Cardiol Therapeutics’ Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association

Results demonstrate CardiolRx™ may represent a paradigm shift in the treatment of patients with recurrent pericarditis and further validate the ongoing Phase III trial, which recently surpassed 75% enrollment. Toronto, ON – May 7, 2026 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that the results from its Phase II study evaluating CardiolRx™ in patients with recurrent pericarditis have been accepted for publication in a forthcoming issue of the Journal of the American Heart Association (“JAHA”). The peer-reviewed publication highlights clinical findings demonstrating that treatment with CardiolRx™ was associated with rapid and sustained reductions in pericarditis pain and inflammation in patients with a high baseline disease burden. The study also reported a substantial reduction in pericarditis episodes per year and a favorable safety and tolerability profile, supporting its continued development in a Phase III program. These findings provide important clinical rationale for the ongoing pivotal Phase III MAVERIC trial (“MAVERIC”), evaluating CardiolRx™ in patients with recurrent pericarditis, which recently surpassed 75% enrollment. “The upcoming publication provides important independent validation of the clinical findings generated in our Phase II MAvERIC study and further supports the potential of CardiolRx™ as a differentiated, non-immunosuppressive therapy for recurrent pericarditis,” said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. “Publication in the Journal of the American Heart Association underscores the clinical relevance of the observed reductions in pericarditis pain and inflammation, together with the favorable safety and tolerability profile demonstrated in this patient population. We believe these data strengthen the foundation for MAVERIC and reinforce the broader opportunity for CardiolRx™ to address a significant unmet medical need in recurrent pericarditis.” The Phase II MAvERIC results published in JAHA represent another important step in advancing clinical understanding of the potential role of CardiolRx™ in the treatment of inflammation-driven heart diseases and helped inform the design and advancement of MAVERIC, a randomized, double-blind, placebo-controlled, pivotal Phase III trial evaluating CardiolRx™ for the prevention of recurrent pericarditis. About Pericarditis Pericarditis refers to inflammation of the pericardium (the membrane or sac that surrounds the heart), which frequently results from a viral infection. Patients may have multiple recurrences following that initial episode, and the primary goal of treatment is recurrence prevention. Symptoms include debilitating chest pain, shortness of breath and fatigue, resulting in physical limitations, reduced quality of life, emergency department visits, and hospitalizations. Current treatment options are limited and often involve prolonged use of immunosuppressive therapies including corticosteroids and injectable biologics, which are associated with risk of significant side effects and dependency. On an annual basis, the number of patients in the United States experiencing at least one recurrence is estimated at 40,000. Approximately 60% of patients with more than one recurrence suffer for more than two years, and one third remain impacted at five years. About Cardiol Therapeutics Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis. The ARCHER Program also studied CardiolRx™ in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population. The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year. For more information about Cardiol Therapeutics, please visit cardiolrx.com. Cautionary statement regarding forward-looking information: This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are “forward-looking information”. Forward looking information contained herein may include, but is not limited to statements regarding the Company’s focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company’s intended clinical studies and trial activities and timelines associated with such activities, including the Company’s plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company’s plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure, including through the initiation of a Phase I clinical program; the Company’s belief that the upcoming publication provides important independent validation of the clinical findings generated in the Phase II MAvERIC study, underscores the clinical relevance of the observed reductions in pericarditis pain and inflammation, together with the favorable safety and tolerability profile demonstrated in this patient population, further supports the potential of CardiolRx™ as a differentiated, non-immunosuppressive therapy for recurrent pericarditis, validates and provides important clinical rationale for the ongoing pivotal Phase III MAVERIC trial, reinforces the broader opportunity to improve treatment options for patients and are an important step in disseminating and advancing clinical understanding of the potential role of CardiolRx™ in the treatment of inflammation-driven heart diseases; the Company’s expectation that MAVERIC will support an NDA with the U.S. FDA.; and the Company’s ability to address its strategic priorities. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements. For further information, please contact: [email protected] Press Releases Press Release Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities CommissionSeptember 10, 2026 Press Release Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 9, 2026 Press Release Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity’s 46th Annual Growth ConferenceAugust 5, 2026 View all Join our newsletter Sign up to receive the latest news from Cardiol Therapeutics! By subscribing you agree to with our Privacy Policy Name(Required) First Last Email(Required) CAPTCHA Subscribe gform.initializeOnLoaded( function() {jQuery('#gform_ajax_frame_8').on('load',function(){var contents = jQuery(this).contents().find('*').html();var is_postback = contents.indexOf('GF_AJAX_POSTBACK') >= 0;if(!is_postback){return;}var form_content = jQuery(this).contents().find('#gform_wrapper_8');var is_confirmation = jQuery(this).contents().find('#gform_confirmation_wrapper_8').length > 0;var is_redirect = contents.indexOf('gformRedirect(){') >= 0;var is_form = form_content.length > 0 && ! is_redirect && ! is_confirmation;var mt = parseInt(jQuery('html').css('margin-top'), 10) + parseInt(jQuery('body').css('margin-top'), 10) + 100;if(is_form){jQuery('#gform_wrapper_8').html(form_content.html());if(form_content.hasClass('gform_validation_error')){jQuery('#gform_wrapper_8').addClass('gform_validation_error');} else {jQuery('#gform_wrapper_8').removeClass('gform_validation_error');}setTimeout( function() { /* delay the scroll by 50 milliseconds to fix a bug in chrome */ jQuery(document).scrollTop(jQuery('#gform_wrapper_8').offset().top - mt); }, 50 );var current_page = jQuery('#gform_source_page_number_8').val();jQuery(document).trigger('gform_page_loaded', [8, current_page]);window['gf_submitting_8'] = false;}else if(!is_redirect){var confirmation_content = jQuery(this).contents().find('.GF_AJAX_POSTBACK').html();if(!confirmation_content){confirmation_content = contents;}jQuery('#gform_wrapper_8').replaceWith(confirmation_content);jQuery(document).scrollTop(jQuery('#gf_8').offset().top - mt);jQuery(document).trigger('gform_confirmation_loaded', [8]);window['gf_submitting_8'] = false;wp.a11y.speak(jQuery('#gform_confirmation_message_8').text());}else{jQuery('#gform_8').append(contents);if(window['gformRedirect']) {gformRedirect();}}jQuery(document).trigger("gform_pre_post_render", [{ formId: "8", currentPage: "current_page", abort: function() { this.preventDefault(); } }]); if (event && event.defaultPrevented) { return; } const gformWrapperDiv = document.getElementById( "gform_wrapper_8" ); if ( gformWrapperDiv ) { const visibilitySpan = document.createElement( "span" ); visibilitySpan.id = "gform_visibility_test_8"; gformWrapperDiv.insertAdjacentElement( "afterend", visibilitySpan ); } const visibilityTestDiv = document.getElementById( "gform_visibility_test_8" ); let postRenderFired = false; function triggerPostRender() { if ( postRenderFired ) { return; } postRenderFired = true; gform.core.triggerPostRenderEvents( 8, current_page ); if ( visibilityTestDiv ) { visibilityTestDiv.parentNode.removeChild( visibilityTestDiv ); } } function debounce( func, wait, immediate ) { var timeout; return function() { var context = this, args = arguments; var later = function() { timeout = null; if ( !immediate ) func.apply( context, args ); }; var callNow = immediate && !timeout; clearTimeout( timeout ); timeout = setTimeout( later, wait ); if ( callNow ) func.apply( context, args ); }; } const debouncedTriggerPostRender = debounce( function() { triggerPostRender(); }, 200 ); if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) { const observer = new MutationObserver( ( mutations ) => { mutations.forEach( ( mutation ) => { if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) { debouncedTriggerPostRender(); observer.disconnect(); } }); }); observer.observe( document.body, { attributes: true, childList: false, subtree: true, attributeFilter: [ 'style', 'class' ], }); } else { triggerPostRender(); } } );} ); Company Company Management Team Board of Directors Scientific Advisory Board Our Advisors Collaborators Our Focus Pericarditis Myocarditis Heart Failure The Inflammasome Pipeline Clinical Trials CardiolRx™ CRD-38 Partnering Insights Blog Community Engagement Resources Investors Events & Presentations Press Releases Analyst Coverage Stock Information Filings & Financials Corporate Governance FAQ Contact Us .cls-1{fill:#fff;} 2026 Cardiol Therapeutics. All right reserved. {"prefetch":[{"source":"document","where":{"and":[{"href_matches":"/*"},{"not":{"href_matches":["/wp-*.php","/wp-admin/*","/wp-content/uploads/*","/wp-content/*","/wp-content/plugins/*","/wp-content/themes/cardiolrebuild/*","/*\\?(.+)"]}},{"not":{"selector_matches":"a[rel~=\"nofollow\"]"}},{"not":{"selector_matches":".no-prefetch, .no-prefetch a"}}]},"eagerness":"conservative"}]} (function(d,s,i,r) { if (d.getElementById(i)){return;} var n=d.createElement(s),e=d.getElementsByTagName(s)[0]; n.id=i;n.src='//js.hs-analytics.net/analytics/'+(Math.ceil(new Date()/r)*r)+'/343442423.js'; e.parentNode.insertBefore(n, e); })(document,"script","hs-analytics",300000); var ajax_obj = {"ajax_url":"https://www.cardiolrx.com/wp-admin/admin-ajax.php","nonce":"de3b463ba4"}; //# sourceURL=functions-js-extra wp.i18n.setLocaleData( { 'text direction\u0004ltr': [ 'ltr' ] } ); //# sourceURL=wp-i18n-js-after var gform_i18n = {"datepicker":{"wdOffset":1,"helpTextShort":"Press F1 for help","helpText":"Press the arrow keys to navigate by day, PageUp and PageDown to navigate by month, Alt+PageUp and Alt+PageDown to navigate by year, or Escape to cancel.","openOnFocusHelpText":"Press Down arrow to browse the calendar, or Escape to close.","tooltipTxt":"Press Escape to cancel","disabledTxt":"Disabled","markedTxt":"Selected","prevTxt":"Previous","nextTxt":"Next","monthTxt":"Month","yearTxt":"Year","months":["January","February","March","April","May","June","July","August","September","October","November","December"],"days":[{"s":"S","l":"Sunday"},{"s":"M","l":"Monday"},{"s":"T","l":"Tuesday"},{"s":"W","l":"Wednesday"},{"s":"T","l":"Thursday"},{"s":"F","l":"Friday"},{"s":"S","l":"Saturday"}]}}; var gf_legacy_multi = []; var gform_gravityforms = {"strings":{"invalid_file_extension":"This type of file is not allowed. Must be one of the following:","file_uploaded":"File uploaded","delete_file":"Delete this file","in_progress":"in progress","file_exceeds_limit":"File exceeds size limit","illegal_extension":"This type of file is not allowed.","max_reached":"Maximum number of files reached","unknown_error":"There was a problem while saving the file on the server","currently_uploading":"Please wait for the uploading to complete","cancel":"Cancel","cancel_upload":"Cancel this upload","cancelled":"Cancelled","error":"Error","message":"Message"},"vars":{"images_url":"https://www.cardiolrx.com/wp-content/plugins/gravityforms/images"}}; var gf_global = {"gf_currency_config":{"name":"U.S. Dollar","symbol_left":"$","symbol_right":"","symbol_padding":"","thousand_separator":",","decimal_separator":".","decimals":2,"code":"USD"},"base_url":"https://www.cardiolrx.com/wp-content/plugins/gravityforms","number_formats":[],"version_hash":"bd2ea601f0155d066a4f3802a65e82de","countries":{"AF":"Afghanistan","AX":"\u00c5land Islands","AL":"Albania","DZ":"Algeria","AS":"American Samoa","AD":"Andorra","AO":"Angola","AI":"Anguilla","AQ":"Antarctica","AG":"Antigua and Barbuda","AR":"Argentina","AM":"Armenia","AW":"Aruba","AU":"Australia","AT":"Austria","AZ":"Azerbaijan","BS":"Bahamas","BH":"Bahrain","BD":"Bangladesh","BB":"Barbados","BY":"Belarus","BE":"Belgium","BZ":"Belize","BJ":"Benin","BM":"Bermuda","BT":"Bhutan","BO":"Bolivia","BQ":"Bonaire, Sint Eustatius and Saba","BA":"Bosnia and Herzegovina","BW":"Botswana","BV":"Bouvet Island","BR":"Brazil","IO":"British Indian Ocean Territory","BN":"Brunei Darussalam","BG":"Bulgaria","BF":"Burkina Faso","BI":"Burundi","CV":"Cabo Verde","KH":"Cambodia","CM":"Cameroon","CA":"Canada","KY":"Cayman Islands","CF":"Central African Republic","TD":"Chad","CL":"Chile","CN":"China","CX":"Christmas Island","CC":"Cocos Islands","CO":"Colombia","KM":"Comoros","CD":"Congo, Democratic Republic of the","CG":"Congo","CK":"Cook Islands","CR":"Costa Rica","CI":"C\u00f4te d'Ivoire","HR":"Croatia","CU":"Cuba","CW":"Cura\u00e7ao","CY":"Cyprus","CZ":"Czechia","DK":"Denmark","DJ":"Djibouti","DM":"Dominica","DO":"Dominican Republic","EC":"Ecuador","EG":"Egypt","SV":"El Salvador","GQ":"Equatorial Guinea","ER":"Eritrea","EE":"Estonia","SZ":"Eswatini","ET":"Ethiopia","FK":"Falkland Islands","FO":"Faroe Islands","FJ":"Fiji","FI":"Finland","FR":"France","GF":"French Guiana","PF":"French Polynesia","TF":"French Southern Territories","GA":"Gabon","GM":"Gambia","GE":"Georgia","DE":"Germany","GH":"Ghana","GI":"Gibraltar","GR":"Greece","GL":"Greenland","GD":"Grenada","GP":"Guadeloupe","GU":"Guam","GT":"Guatemala","GG":"Guernsey","GN":"Guinea","GW":"Guinea-Bissau","GY":"Guyana","HT":"Haiti","HM":"Heard Island and McDonald Islands","VA":"Holy See","HN":"Honduras","HK":"Hong Kong","HU":"Hungary","IS":"Iceland","IN":"India","ID":"Indonesia","IR":"Iran","IQ":"Iraq","IE":"Ireland","IM":"Isle of Man","IL":"Israel","IT":"Italy","JM":"Jamaica","JP":"Japan","JE":"Jersey","JO":"Jordan","KZ":"Kazakhstan","KE":"Kenya","KI":"Kiribati","KP":"Korea, Democratic People's Republic of","KR":"Korea, Republic of","KW":"Kuwait","KG":"Kyrgyzstan","LA":"Lao People's Democratic Republic","LV":"Latvia","LB":"Lebanon","LS":"Lesotho","LR":"Liberia","LY":"Libya","LI":"Liechtenstein","LT":"Lithuania","LU":"Luxembourg","MO":"Macao","MG":"Madagascar","MW":"Malawi","MY":"Malaysia","MV":"Maldives","ML":"Mali","MT":"Malta","MH":"Marshall Islands","MQ":"Martinique","MR":"Mauritania","MU":"Mauritius","YT":"Mayotte","MX":"Mexico","FM":"Micronesia","MD":"Moldova","MC":"Monaco","MN":"Mongolia","ME":"Montenegro","MS":"Montserrat","MA":"Morocco","MZ":"Mozambique","MM":"Myanmar","NA":"Namibia","NR":"Nauru","NP":"Nepal","NL":"Netherlands","NC":"New Caledonia","NZ":"New Zealand","NI":"Nicaragua","NE":"Niger","NG":"Nigeria","NU":"Niue","NF":"Norfolk Island","MK":"North Macedonia","MP":"Northern Mariana Islands","NO":"Norway","OM":"Oman","PK":"Pakistan","PW":"Palau","PS":"Palestine, State of","PA":"Panama","PG":"Papua New Guinea","PY":"Paraguay","PE":"Peru","PH":"Philippines","PN":"Pitcairn","PL":"Poland","PT":"Portugal","PR":"Puerto Rico","QA":"Qatar","RE":"R\u00e9union","RO":"Romania","RU":"Russian Federation","RW":"Rwanda","BL":"Saint Barth\u00e9lemy","SH":"Saint Helena, Ascension and Tristan da Cunha","KN":"Saint Kitts and Nevis","LC":"Saint Lucia","MF":"Saint Martin","PM":"Saint Pierre and Miquelon","VC":"Saint Vincent and the Grenadines","WS":"Samoa","SM":"San Marino","ST":"Sao Tome and Principe","SA":"Saudi Arabia","SN":"Senegal","RS":"Serbia","SC":"Seychelles","SL":"Sierra Leone","SG":"Singapore","SX":"Sint Maarten","SK":"Slovakia","SI":"Slovenia","SB":"Solomon Islands","SO":"Somalia","ZA":"South Africa","GS":"South Georgia and the South Sandwich Islands","SS":"South Sudan","ES":"Spain","LK":"Sri Lanka","SD":"Sudan","SR":"Suriname","SJ":"Svalbard and Jan Mayen","SE":"Sweden","CH":"Switzerland","SY":"Syria Arab Republic","TW":"Taiwan","TJ":"Tajikistan","TZ":"Tanzania, the United Republic of","TH":"Thailand","TL":"Timor-Leste","TG":"Togo","TK":"Tokelau","TO":"Tonga","TT":"Trinidad and Tobago","TN":"Tunisia","TR":"T\u00fcrkiye","TM":"Turkmenistan","TC":"Turks and Caicos Islands","TV":"Tuvalu","UG":"Uganda","UA":"Ukraine","AE":"United Arab Emirates","GB":"United Kingdom","US":"United States","UY":"Uruguay","UM":"US Minor Outlying Islands","UZ":"Uzbekistan","VU":"Vanuatu","VE":"Venezuela","VN":"Viet Nam","VG":"Virgin Islands, British","VI":"Virgin Islands, U.S.","WF":"Wallis and Futuna","EH":"Western Sahara","YE":"Yemen","ZM":"Zambia","ZW":"Zimbabwe"},"strings":{"newRowAdded":"New row added.","rowRemoved":"Row removed","formSaved":"The form has been saved. The content contains the link to return and complete the form."}}; //# sourceURL=gform_gravityforms-js-extra var gform_theme_config = {"common":{"form":{"honeypot":{"version_hash":"bd2ea601f0155d066a4f3802a65e82de"},"ajax":{"ajaxurl":"https://www.cardiolrx.com/wp-admin/admin-ajax.php","ajax_submission_nonce":"d21fa2eb7e","i18n":{"step_announcement":"Step %1$s of %2$s, %3$s","unknown_error":"There was an unknown error processing your request. Please try again.","error_403":"The request was blocked (403 error) for unknown security reasons. Remove any code-like text (scripts or DB queries) and try again."}}}},"hmr_dev":"","public_path":"https://www.cardiolrx.com/wp-content/plugins/gravityforms/assets/js/dist/","config_nonce":"424d34be2f"}; //# sourceURL=gform_gravityforms_theme-js-extra {"baseUrl":"https://s.w.org/images/core/emoji/17.0.2/72x72/","ext":".png","svgUrl":"https://s.w.org/images/core/emoji/17.0.2/svg/","svgExt":".svg","source":{"concatemoji":"https://www.cardiolrx.com/wp-includes/js/wp-emoji-release.min.js?ver=7.1"}} /*! This file is auto-generated */ var e="script#wp-emoji-settings",t=document.querySelector(e);if(!(t instanceof HTMLScriptElement))throw new Error("Element missing: "+e);const r=JSON.parse(t.text),s=(window._wpemojiSettings=r,"wpEmojiSettingsSupports"),o=["flag","emoji"];function i(e){try{var t={supportTests:e,timestamp:(new Date).valueOf()};sessionStorage.setItem(s,JSON.stringify(t))}catch(e){}}function c(e,t,n){e.clearRect(0,0,e.canvas.width,e.canvas.height),e.fillText(t,0,0);t=new Uint32Array(e.getImageData(0,0,e.canvas.width,e.canvas.height).data);e.clearRect(0,0,e.canvas.width,e.canvas.height),e.fillText(n,0,0);const r=new Uint32Array(e.getImageData(0,0,e.canvas.width,e.canvas.height).data);return t.every((e,t)=>e===r[t])}function p(e,t){e.clearRect(0,0,e.canvas.width,e.canvas.height),e.fillText(t,0,0);var n=e.getImageData(16,16,1,1);for(let e=0;e<n.data.length;e++)if(0!==n.data[e])return!1;return!0}function u(e,t,n,r){switch(t){case"flag":return n(e,"\ud83c\udff3\ufe0f\u200d\u26a7\ufe0f","\ud83c\udff3\ufe0f\u200b\u26a7\ufe0f")?!1:!n(e,"\ud83c\udde8\ud83c\uddf6","\ud83c\udde8\u200b\ud83c\uddf6")&&!n(e,"\ud83c\udff4\udb40\udc67\udb40\udc62\udb40\udc65\udb40\udc6e\udb40\udc67\udb40\udc7f","\ud83c\udff4\u200b\udb40\udc67\u200b\udb40\udc62\u200b\udb40\udc65\u200b\udb40\udc6e\u200b\udb40\udc67\u200b\udb40\udc7f");case"emoji":return!r(e,"\ud83e\u1fac8")}return!1}function f(e,t,n,r){let a;const s=(a="undefined"!=typeof WorkerGlobalScope&&self instanceof WorkerGlobalScope?new OffscreenCanvas(300,150):document.createElement("canvas")).getContext("2d",{willReadFrequently:!0}),o=(s.textBaseline="top",s.font="600 32px Arial",{});return e.forEach(e=>{o[e]=t(s,e,n,r)}),o}function a(e){var t=document.createElement("script");t.src=e,t.defer=!0,document.head.appendChild(t)}r.supports={everything:!0,everythingExceptFlag:!0},new Promise(t=>{let n=function(){try{var e=JSON.parse(sessionStorage.getItem(s));if("object"==typeof e&&"number"==typeof e.timestamp&&(new Date).valueOf()<e.timestamp+604800&&"object"==typeof e.supportTests)return e.supportTests}catch(e){}return null}();if(!n){if("undefined"!=typeof Worker&&"undefined"!=typeof OffscreenCanvas&&"undefined"!=typeof URL&&URL.createObjectURL&&"undefined"!=typeof Blob)try{var e="postMessage("+f.toString()+"("+[JSON.stringify(o),u.toString(),c.toString(),p.toString()].join(",")+"));",r=new Blob([e],{type:"text/javascript"});const a=new Worker(URL.createObjectURL(r),{name:"wpTestEmojiSupports"});return void(a.onmessage=e=>{i(n=e.data),a.terminate(),t(n)})}catch(e){}i(n=f(o,u,c,p))}t(n)}).then(e=>{for(const n in e)r.supports[n]=e[n],r.supports.everything=r.supports.everything&&r.supports[n],"flag"!==n&&(r.supports.everythingExceptFlag=r.supports.everythingExceptFlag&&r.supports[n]);var t;r.supports.everythingExceptFlag=r.supports.everythingExceptFlag&&!r.supports.flag,r.supports.everything||((t=r.source||{}).concatemoji?a(t.concatemoji):t.wpemoji&&t.twemoji&&(a(t.twemoji),a(t.wpemoji)))}); //# sourceURL=https://www.cardiolrx.com/wp-includes/js/wp-emoji-loader.min.js gform.initializeOnLoaded( function() { jQuery(document).on('gform_post_render', function(event, formId, currentPage){if(formId == 8) {if(typeof Placeholders != 'undefined'){ Placeholders.enable(); }} } );jQuery(document).on('gform_post_conditional_logic', function(event, formId, fields, isInit){} ) } ); gform.initializeOnLoaded( function() {jQuery(document).trigger("gform_pre_post_render", [{ formId: "8", currentPage: "1", abort: function() { this.preventDefault(); } }]); if (event && event.defaultPrevented) { return; } const gformWrapperDiv = document.getElementById( "gform_wrapper_8" ); if ( gformWrapperDiv ) { const visibilitySpan = document.createElement( "span" ); visibilitySpan.id = "gform_visibility_test_8"; gformWrapperDiv.insertAdjacentElement( "afterend", visibilitySpan ); } const visibilityTestDiv = document.getElementById( "gform_visibility_test_8" ); let postRenderFired = false; function triggerPostRender() { if ( postRenderFired ) { return; } postRenderFired = true; gform.core.triggerPostRenderEvents( 8, 1 ); if ( visibilityTestDiv ) { visibilityTestDiv.parentNode.removeChild( visibilityTestDiv ); } } function debounce( func, wait, immediate ) { var timeout; return function() { var context = this, args = arguments; var later = function() { timeout = null; if ( !immediate ) func.apply( context, args ); }; var callNow = immediate && !timeout; clearTimeout( timeout ); timeout = setTimeout( later, wait ); if ( callNow ) func.apply( context, args ); }; } const debouncedTriggerPostRender = debounce( function() { triggerPostRender(); }, 200 ); if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) { const observer = new MutationObserver( ( mutations ) => { mutations.forEach( ( mutation ) => { if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) { debouncedTriggerPostRender(); observer.disconnect(); } }); }); observer.observe( document.body, { attributes: true, childList: false, subtree: true, attributeFilter: [ 'style', 'class' ], }); } else { triggerPostRender(); } } );

The release as fetched from its publisher. cardiolrx.com ↗